Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Natera (NTRA) entered a clinical collaboration agreement with Incyte (INCY) for a phase II study in colorectal cancer. The trial will evaluate Incyte’s investigational bispecific immunotherapy, INCA33890, in patients with stage 2/3 disease who have completed surgery and adjuvant chemotherapy, treatment given after surgery. Natera’s Signatera test will be incorporated as both a primary and secondary endpoint, measures used to assess the study.
After chemotherapy, patients will undergo repeated Signatera testing for up to 12 months. Those testing positive for molecular residual disease (MRD), with no evidence of disease on imaging, may be eligible for enrollment and treatment. Natera will also provide trial matching services based on Signatera MRD status and other eligibility criteria.
Merck (NYSE: MRK) reported worldwide sales of $18.1 billion, up 5%, and narrowed its sales outlook while raising the midpoint. Its expected sales range is $66.8 billion–$67.3 billion. KEYTRUDA/KEYTRUDA QLEX sales were $8.6 billion; WINREVAIR sales rose 93% to $694 million.
Other drugmakers also reported growth: Amgen's third-quarter revenue rose 8% to $10.4 billion, Vertex's rose 12% to $3.44 billion, and Incyte's rose 14% to $1.56 billion. Gilead's product sales excluding Veklury increased 16% year over year to $8.2 billion. Gilead, Vertex and Incyte raised their full-year sales or revenue outlooks. Pricing pressures included a 14% decline in Amgen's Enbrel net selling price; Gilead expects a new Medicare price to affect Biktarvy revenue starting January 1, 2028.
The Nasdaq Biotechnology Index rose 2.1% as of 2:31 p.m. ET on November 4, alongside a broader market rally.
Incyte (INCY) will present hematology data at the American Society of Hematology annual meeting on December 12–15, 2026, in New Orleans. More than 30 abstracts will cover its portfolio, including Phase 1 findings for INCA033989 in myelofibrosis and essential thrombocythemia, both bone marrow disorders, and preclinical findings for next-generation compounds.
Presentations also include long-term Phase 1/2 results for latarcibart in adolescents and adults with von Willebrand disease, a bleeding disorder, alongside axatilimab and tafasitamab studies. Incyte will host an analyst and investor event with a webcast on December 12 from 7:30–9:00 p.m. CT.
Incyte (Nasdaq: INCY) will present at three investor conferences in November, beginning with the Wolfe Research Healthcare Conference on November 10, 2026.
The Wolfe presentation is at 10:00 am EST. On November 17, Incyte will present at the Jefferies Global Healthcare Conference at 9:00 am GMT and the UBS Global Biopharma Conference at 1:20 pm GMT. Live webcasts will be available at Investor.Incyte.com, with replays available for 30 days.
Incyte (Nasdaq: INCY) reported third-quarter 2026 revenue of $1.56 billion, up 14% from the same period in 2025. Total net sales rose 14% to $1.32 billion. Jakafi/Jakafi XR sales increased 4% to $827 million, Opzelura rose 36% to $255 million, and Hematology and Oncology rose 38% to $235 million.
Incyte raised its 2026 total net sales outlook to $5,210–$5,300 million, with higher Opzelura and Hematology and Oncology forecasts. GAAP research and development expenses increased 254% to $1.79 billion, including a $1.23 billion acquired research charge for Vega Therapeutics. The July acquisition cost $1.25 billion, with up to $750 million in additional sales milestone payments. Cash and marketable securities totaled $3.9 billion at September 30. Incyte expects fourth-quarter Phase 3 results for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa, an inflammatory skin condition.
Incyte (INCY) reported Phase 1 pancreatic and colorectal cancer results for INCB161734 and INCA33890 at ESMO 2026, alongside development plans.
In pancreatic cancer, INCB161734 plus chemotherapy produced six-month progression-free survival rates of 90% with mFOLFIRINOX and 80% with gemcitabine/nab-paclitaxel. In previously treated colorectal cancer, INCB161734 plus cetuximab achieved a 36% objective response rate, measuring tumor shrinkage. INCA33890 plus FOLFOX and bevacizumab achieved a 71% response rate in first-line microsatellite stable colorectal cancer. Adverse events included gastrointestinal symptoms and reduced blood-cell counts.
Incyte expects Phase 3 DAWN-303 pancreatic cancer results in 2028 and NEXERA-303 colorectal cancer results in 2029, and plans to initiate DAWN-302 in the first half of 2027. New pancreatic cancer collaborations involve Bristol Myers Squibb and Synnovation.
Incyte (INCY) and Genmab (GMAB) announced a clinical trial collaboration to evaluate a combination treatment for metastatic colorectal cancer. The planned Phase 1/2 study will evaluate Incyte’s INCB161734 with Genmab’s petosemtamab and standard-of-care chemotherapy as first-line treatment for patients whose cancers carry the KRAS G12D mutation.
Genmab will conduct the study, while Incyte will co-fund it and supply INCB161734. The companies aim to investigate whether combining agents with different mechanisms and chemotherapy could provide a new treatment approach. INCB161734 targets KRAS G12D; petosemtamab targets EGFR and LGR5, proteins involved in cancer biology. Separately, petosemtamab is being evaluated with chemotherapy in two Phase 3 trials in first- and second-line metastatic colorectal cancer without RAS/BRAF mutations.
Incyte (INCY) will present oncology data at the ESMO Congress in Madrid, taking place October 23–27, 2026. Four rapid oral presentations cover INCB161734 in colorectal and pancreatic cancers, INCA33890 in colorectal cancer, and INCB123667 in ovarian cancer. The company will also host an investor event and webcast on October 26 to discuss the data and provide portfolio updates.
Incyte (Nasdaq: INCY) has scheduled its third-quarter financial results conference call and webcast for October 29, 2026. The Q3 2026 results release is scheduled for 7:00 a.m. ET, followed by the call at 8:00 a.m. ET. A live webcast with slides will be available at Investor.Incyte.com.
MiniMed (MMED) appointed Sheila Denton general counsel and corporate secretary, effective immediately, succeeding Courtney Nelson Wills.
Denton most recently held both roles and served on the executive team at Incyte (INCY). Wills left MiniMed to pursue new professional opportunities.